β-Amyloid-related peptides potentiate K+-evoked glutamate release from adult rat hippocampal slices

Neurobiology of Aging

Volumn 31, Issue 7, 2010, Pages 1164-1172

  Kabogo, D ^a   Rauw, G ^a   Amritraj, A ^a   Baker, G ^a   Kar, S ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Alzheimer's disease; Amyloid peptide; Cortex; Hippocampus; Neuromodulation; Neurotransmitter release; NMDA receptor; Striatum

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-28]; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN[25-35]; AMYLOID PRECURSOR PROTEIN; GLUTAMIC ACID; POTASSIUM; TETRODOTOXIN; UNCLASSIFIED DRUG; VESICULAR GLUTAMATE TRANSPORTER 1; VOLTAGE GATED SODIUM CHANNEL; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT; SLC17A7 PROTEIN, RAT;

ADULT ANIMAL; ALZHEIMER DISEASE; ANIMAL TISSUE; ARTICLE; COGNITIVE DEFECT; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS STRIATUM; FRONTAL CORTEX; HIPPOCAMPUS; MALE; NERVE DEGENERATION; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RAT; ANIMAL; METABOLISM; ORGAN CULTURE TECHNIQUE; PHYSIOLOGY; SECRETION; SPRAGUE DAWLEY RAT; SYNAPTOSOME;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; GLUTAMIC ACID; HIPPOCAMPUS; MALE; ORGAN CULTURE TECHNIQUES; PEPTIDE FRAGMENTS; POTASSIUM; PRESYNAPTIC TERMINALS; RATS; RATS, SPRAGUE-DAWLEY; VESICULAR GLUTAMATE TRANSPORT PROTEIN 1;

EID: 77952880350     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2008.08.009     Document Type: Article

References (66)

1. Araujo D.M., Lapchak P.A., Collier B., Chabot J.-G., Quirion R. Insulin-like growth factor-I (somatomedin-C) receptors in the rat brain distribution and interaction with the hippocampal cholinergic system. Brain Res. 1989, 484:130-138.
2. Arias C., Arrirta I., Tapia R. β-Amyloid peptide fragment 25-35 potentiates the calcium-dependent release of excitatory amino acids from depolarized hippocampal slices. J. Neurosci. Res. 1995, 41:561-566.
3. Beeson J.G., Shelton E.R., Chan H.W., Gage F.H. Differential distribution of amyloid protein precursor immunoreactivity in the rat brain studied by using five different antibodies. J. Comp. Neurol. 1994, 342:78-96.
4. Bell K.F., Bennett D.A., Cuello A.C. Paradoxical upregulation of glutamatergic presynaptic boutons during mild cognitive impairment. J. Neurosci. 2007, 27:10810-10817.
5. Braak E., Griffing K., Arai K., Bohl J., Bratzke H., Braak H. Neuropathology of Alzheimer's disease: what is new since A. Alzheimer?. Eur. Arch. Psychiatry Clin. Neurosci. 1999, 249(Suppl. 3):14-22.
6. 1-42 activates CaV2.2(N-Type)-voltage operated calcium channels and acutely increases glutamate and noradrenaline release. J. Alzheimers Dis. 2004, 6:243-255.
7. Butterfield D.A., Pocernich C.B. The glutamatergic system and Alzheimer's disease: therapeutic implications. CNS Drugs 2003, 17:641-652.
8. Cacabelos R., Takeda M., Winblad B. The glutamatergic system and neurodegeneration in dementia: preventive strategies in Alzheimer's disease. Int. J. Geriatr. Psychiatry 1999, 14:3-47.
9. Clippingdale A.B., Wade J.D., Barrow C.J. The amyloid-β peptide and its role in Alzheimer's disease. J. Peptide Sci. 2001, 7:227-249.
10. Cosman K.M., Boyle L.L., Porsteinsson A.P. Memantine in the treatment of mild-to-moderate Alzheimer's disease. Expert Opin. Pharmacother. 2007, 8:203-214.
11. D'Andrea M.R., Nagele R.G. Targeting the alpha 7 nicotinic acetylcholine receptor to reduce amyloid accumulation in Alzheimer's disease pyramidal neurons. Curr. Pharm. Design 2006, 12:677-684.
12. El Khoury J., Hickman S.E., Thomas C.A., Cao L., Silverstein S.C., Loike J.D. Scavenger receptor-mediated adhesion of microglia to β-amyloid fibrils. Nature 1996, 382:716-719.
13. Farlow M.R. NMDA receptor antagonists. A new therapeutic approach for Alzheimer's disease. Geriatrics 2004, 59:22-27.
14. Farr S.A., Banks W.A., Uezy K., Sano A., Gaskin F.S., Morley J.E. Antibody to β-amyloid protein increases acetylcholine in the hippocampus of 12 month SAMP8 male mice. Life Sci. 2003, 73:555-562.
15. 25-35 inhibits glutamate uptake in cultured neurons and astrocytes: modulation of uptake as a survival mechanism. Neurobiol. Dis. 2004, 15:580-589.
16. Floden A.M., Li S., Combs C.K. β-Amyloid-stimulated microglia induce neuron death via synergistic stimulation of tumor necrosis factor α and NMDA receptors. J. Neurosci. 2005, 25:2566-2575.
17. Francis P.T. Glutamatergic systems in Alzheimer's disease. Int. J. Geriatr. Psychiatry 2003, 18:S15-S21.
18. Gray C.W., Patel A.J. Neurodegeneration mediated by glutamate and β-amyloid peptide: a comparison and possible interaction. Brain Res. 1995, 691:169-179.
19. Haass C., Schlossmacher M.G., Hung A.Y., Vigo-Pelfrey C., Mellon A., Ostaszewski B.L., Lieberburg I., Koo E.H., Schenk D., Teplow D.B., Selkoe D.J. Amyloid β-peptide is produced by cultured cells during normal metabolism. Nature 1992, 359:322-325.
20. Harkany T., Abraham I., Timmerman W., Laskay G., Toth B., Sasvari M., Konya C., Sebens J.B., Korf J., Nyakas C., Zarandi M., Soos K., Penke B., Luiten P.G. β-Amyloid neurotoxicity is mediated by a glutamate-triggered excitotoxic cascade in rat nucleus basalis. Eur. J. Neurosci. 2000, 12:2735-2745.
21. +-dependent glutamate uptake in rat hippocampal astrocyte cultures. J. Neurochem. 1996, 67:277-286.
22. Hawkes C., Kar S. Insulin-like growth factor-II/mannose-6-phosphate receptor: widespread distribution in neurons of the central nervous system including those expressing cholinergic phenotype. J. Comp. Neurol. 2003, 458:113-127.
23. Hawkes C., Jhamandas J.H., Harris K.H., Fu W., MacDonald R.G., Kar S. Single transmembrane domain insulin-like growth factor-II/mannose-6-phosphate receptor regulates central cholinergic function by activating a G-protein-sensitive, protein kinase C-dependent pathway. J. Neurosci. 2006, 26:585-596.
24. Herzog E., Takamori S., Jahn R., Brose N., Wojcik S.M. Synaptic and vesicular co-localization of the glutamate transporters VGLUT1 and VGLUT2 in the mouse hippocampus. J. Neurochem. 2006, 99:1011-1018.
25. Hynd M.R., Scott H.L., Dodd P.R. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Neurochem. Int. 2004, 45:583-595.
26. Itoh A., Akaike T., Sokabe M., Nitta A., Nabeshima T. Impairment of long-term potentiation in hippocampal slices of β-amyloid-infused rats. Eur. J. Pharmacol. 1999, 3:167-175.
27. Jhamandas J.H., Harris K.H., Cho C., Fu W., MacTavish D. Human amylin actions on rat cholinergic basal forebrain neurons: antagonism of β-amyloid effects. J. Neurophysiol. 2003, 89:2923-2930.
28. Joslin G., Krause J.E., Hershey A.D., Adams S.P., Fallon R.J., Perlmutter D.H. Amyloid-β peptide, substance, and bombesin bind to the serpin-enzyme complex receptor. J. Biol. Chem. 1991, 266:21897-21902.
29. Kaneko T., Fujiyama F., Hioki H. Immunohistochemical localization of candidates for vesicular glutamate transporters in the rat brain. J. Comp. Neurol. 2002, 444:39-62.
30. Kar S., Seto D., Gaudreau P., Quirion R. β-Amyloid-related peptides inhibit potassium-evoked acetylcholine release from rat hippocampal formation. J. Neurosci. 1996, 16:1034-1040.
31. Kar S., Issa A.M., Seto D., Auld D.S., Collier B., Quirion R. Amyloid β-peptide inhibits high-affinity choline uptake and acetylcholine release in rat hippocampal slices. J. Neurochem. 1998, 70:2179-2187.
32. Kar S., Slowikowski S.P., Westaway D., Mount H.T. Interactions between β-amyloid and central cholinergic neurons: implication for Alzheimer's disease. J. Psychiatry Neurosci. 2004, 2:427-441.
33. Kuner P., Schubenel R., Hertel C. β-Amyloid binds to p75NTR and activates NFκB in human neuroblastoma cells. J. Neurosci. Res. 1998, 54:798-804.
34. +-dependent glutamate uptake. Life Sci. 1999, 65:1977-1981.
35. Lesne S., Ali C., Gabriel C., Croci N., MacKenzie E.T., Glabe C.G., Plotkine M., Marchand-Verrecchia C., Vivien D., Buisson A. NMDA receptor activation inhibits alpha-secretase and promotes neuronal amyloid-beta production. J. Neurosci. 2005, 25:9367-9377.
36. 3H]norepinephrine and enhances the internal calcium response to low potassium in rat cortex: prevention with a free radical scavenger. Brain Res. Bull. 1996, 39:299-303.
37. Lopez O.L., DeKosky S.T. Neuropathology of Alzheimer's disease and mild cognitive impairment. Rev. Neurol. 2003, 37:155-163.
38. Mattson M.P. Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurodegenerative disorders. Neuromolecular Med. 2003, 3:65-94.
39. Mattson M.P., Cheng B., Davis D., Bryant K., Lieberburg I., Rydel R.E. β-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J. Neurosci. 1992, 12:376-389.
40. Michaelis E.K. Molecular biology of glutamate receptors in the central nervous system and their role in excitotoxicity, oxidative stress and aging. Prog. Neurobiol. 1998, 54:369-415.
41. Minkeviciene R., Ihalainen J., Malm T., Matilainen O., Keksa-Goldsteine V., Goldsteins G., Iivonen H., Leguit N., Glennon J., Koistinaho J., Banerjee P., Tanila H. Age-related decrease in stimulated glutamate release and vesicular glutamate transporters in APP/PS1 transgenic and wild-type mice. J. Neurochem. 2008, 105:584-594.
42. Narahashi T. Chemicals as tools in the study of excitable membranes. Physiol. Rev. 1974, 54:813-889.
43. Noda M., Nakanishi H., Akaike N. Glutamate release from microglia via glutamate transporter is enhanced by amyloid-β peptide. Neuroscience 1999, 92:1465-1474.
44. Okamoto T., Takeda S., Murayama Y., Ogata E., Nishimoto I. Ligand-dependent G protein coupling function of amyloid transmembrane precursor. J. Biol. Chem. 1995, 270:4205-4208.
45. Ouimet C.C., Baerwald K.D., Gandy S.E., Greengard P. Immunocytochemical localization of amyloid precursor protein in rat brain. J. Comp. Neurol. 1994, 348:244-260.
46. Parent M., Bush D., Rauw G., Master S., Vaccarino F., Baker G. Analysis of amino acids and catecholamines, 5-hydroxytryptamine and their metabolites in brain areas in the rat using in vivo microdialysis. Methods 2001, 23:11-20.
47. +-evoked release of acetylcholine from rat brain synaptosomes: analysis by rapid superfusion. J. Neurochem. 1991, 57:636-647.
48. Pereira C., Ferreiro E., Cardoso S.M., de Oliveira C.R. Cell degeneration induced by amyloid-beta peptides: implications for Alzheimer's disease. J. Mol. Neurosci. 2004, 23:97-104.
49. Robinson D.M., Keating G.M. Memantine: a review of its use in Alzheimer's disease. Drugs 2006, 66:1515-1534.
50. Rogawski M.A., Wenk G.L. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug. Rev. 2003, 9:275-308.
51. Selkoe D.J., Schenk D. Alzheimer's disease: molecular understanding predicts amyloid based therapeutics. Annu. Rev. Pharmacol. Toxicol. 2003, 43:545-584.
52. Shaked G.M., Kummer M.P., Lu D.C., Galvan V., Bredesen D.E., Koo E.H. Abeta induces cell death by direct interaction with its cognate extracellular domain on APP (APP 597-624). FASEB J. 2006, 20:1254-1256.
53. Shoji M., Golde T.E., Ghiso J., Cheung T.T., Estus S., Shaffer L.M., Cai X.D., Makay D.M., Tintner R., Frangione B., Younkin S.G. Production of Alzheimer's β protein by normal proteolytic processing. Science 1992, 258:126-129.
54. Snyder E.M., Nong Y., Almeida C.G., Paul S., Moran T., Choi E.Y., Nairn A.C., Salter M.W., Lombroso P.J., Gouras G.K., Greengard P. Regulation of NMDA receptor trafficking by amyloid-β. Nat. Neurosci. 2005, 8:1051-1058.
55. Stephan A., Laroche S., Davis S. Generation of aggregated β-amyloid in the rat hippocampus impairs synaptic transmission and plasticity and causes memory deficits. J. Neurosci. 2001, 21:5703-5714.
56. Tremblay R., Chakravarthy B., Hewitt K., Tauskela J., Morley P., Atkinson T., Durkin J.P. Transient NMDA receptor inactivation provides long-term protection to cultured cortical neurons from a variety of death signals. J. Neurosci. 2000, 20:7183-7192.
57. Vetrivel K.S., Cheng H., Kim S.H., Chen Y., Barnes N.Y., Parent A.T., Sisodia S.S., Thinakaran G. Spatial segregation of gamma-secretase and substrates in distinct membrane domains. J. Biol. Chem. 2005, 280:25892-25900.
58. Walsh D.M., Klyubuin I., Fadeeva J., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., Selkoe D.J. Naturally secreted oligomers of the Alzheimer amyloid β-protein potently inhibit long-term potentiation in vivo. Nature 2002, 416:535-539.
59. Wang C., Lee J.J., Jung H.-H., Zuo Z. Pretreatment with volatile anesthetics, but not with the nonimmobilizer 1,2-dichlorohexafluorocyclobutane, reduced cell injury in rat cerebellar slices after an in vitro simulated ischemia. Brain Res. 2007, 1152:201-208.
60. Wang H.Y., Wild K.D., Shank R.P., Lee D.H. Galanin inhibits acetylcholine release from rat cerebral cortex via a pertussis toxin-sensitive Gi protein. Neuropeptides 1999, 33:197-205.
61. Wang H.Y., Lee D.H., D'Andrea M.R., Peterson P.A., Shank R.P., Reitz A.B. Beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J. Biol. Chem. 2000, 275:5626-5632.
62. Wang Q., Walsh D.M., Rowan M.J., Selkoe D.J., Anwyl R. Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J. Neurosci. 2004, 24:3370-3378.
63. Waxman E.A., Lynch D.R. N-Methyl-d-aspartate receptor subtypes: multiple roles in excitotoxicity and neurological disease. Neuroscientist 2005, 11:37-49.
64. Wilcock G.K. Memantine for the treatment of dementia. Lancet Neurol. 2003, 2:503-505.
65. Yan S.D., Chen X., Fu J., Chen M., Zhu H., Roher A., Slattery T., Zhao L., Nagashima M., Morser J., Migheli A., Nawroth P., Stern D., Schmidt A.M. RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease. Nature 1996, 382:685-691.
66. Yankner B.A. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron 1996, 16:921-932.